Posted on January 12, 2021
Animal health company Huvepharma, Inc. is working to provide new choices – and new possibilities – to the U.S. livestock sector.
Continue ReadingPosted on December 14, 2020
As animal health evolves Huvepharma continues to expand it's fermentation and manufacturing technology in Peshtera, Bulgaria by more then doubling the capacity.
Continue ReadingPosted on December 02, 2020
On Friday, November 20, 2020, Elanco® Animal Health submitted a letter to FDA formally requesting withdrawal of their Citizen Petition. In that Citizen Petition, Elanco requested FDA to pull Monovet® 90, Huvepharma®, Inc.’s brand of monensin, from the market. Elanco, in requesting this withdrawal, has effectively agreed that Monovet® 90 has been proven safe and effective and is bioequivalent to the pioneer monensin
Continue ReadingPosted on November 23, 2020
Huvepharma Inc. introduces AVERT™ NE, an innovative new vaccine to help control necrotic enteritis (NE) due to Clostridium perfringens Type A.
Continue ReadingPosted on November 19, 2020
In July 2019, Huvepharma had the opportunity to bring the first bioequivalent monensin product (Monovet® 90 monensin Type A medicated article) to U.S.
Continue Reading